Skip to main content
Clinical Trials/NCT05209776
NCT05209776
Recruiting
Not Applicable

Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy

University Hospital, Toulouse1 site in 1 country80 target enrollmentFebruary 1, 2022

Overview

Phase
Not Applicable
Intervention
Peripheral immunological assessment on venous blood
Conditions
Arrhythmogenic Right Ventricular Dysplasia
Sponsor
University Hospital, Toulouse
Enrollment
80
Locations
1
Primary Endpoint
Identify the inflammatory components by interleukine1
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.

Detailed Description

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition characterized by right ventricular (RV) dilatation/dysfunction and malignant ventricular arrhythmias. The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. First, presence of subepicardial late gadolinium enhancement sharing the same characteristics as the ones found in myocarditis is common on cardiac magnetic resonance imaging (CMR). Second, clinical pathology findings of inflammatory infiltrates of mononuclear cells are frequent and correlate to the extent and severity of ARVC. Finally, from a biological standpoint, the exploratory study conducted by Campian et al. has shown an exaggerated humoral inflammatory response in peripheral blood whilst anti-desmoglein-2 antibodies (targeting a component of the desmosome) emerge as a sensitive and specific biomarker for ARVC. As specific treatments for ARVC are currently lacking, a better understanding of the humoral pathophysiology of the disease could unlock new therapeutic targets. We recently demonstrated that collecting local cardiomyocytes was feasible through irrigated ablation catheters in patients with ARVC. These steerable catheters may easily map the whole right ventricle and locate endocardial or epicardial scars. Aspiration of local blood or cellular material through the inner lumen of the catheter once pressed on the parietal wall may be an interesting technique for retrieving local inflammation markers.

Registry
clinicaltrials.gov
Start Date
February 1, 2022
End Date
February 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • For cases:
  • Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
  • Admitted for right ventricle electrophysiologic mapping
  • For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.

Exclusion Criteria

  • Diagnostic of systemic chronic inflammatory disease
  • Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
  • Taking immunosuppressant or immunomodulating medications

Arms & Interventions

Patients

Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle

Intervention: Peripheral immunological assessment on venous blood

Patients

Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle

Intervention: Immunological assessment carried out on intracardiac material

Control case

Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).

Intervention: Peripheral immunological assessment on venous blood

Control case

Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).

Intervention: Immunological assessment carried out on intracardiac material

Outcomes

Primary Outcomes

Identify the inflammatory components by interleukine1

Time Frame: 24 months

Rate of interleukin 1 beta in the blood

Identify the inflammatory components by C-reactive protein

Time Frame: 24 months

Rate of C-reactive protein in the blood

Identify the inflammatory components by interleukine10

Time Frame: 24 months

Rate of interleukin 10 in the blood

Identify the inflammatory components by Transforming Growth Factor

Time Frame: 24 months

Rate of Transforming Growth Factor beta in the blood

Identify the inflammatory components by onterleukine6

Time Frame: 24 months

Rate of interleukin 6 in the blood

Identify the inflammatory components by Tumor Necrosis Factor

Time Frame: 24 months

Rate of Tumor Necrosis Factor alpha in the blood

Study Sites (1)

Loading locations...

Similar Trials